参考文献:
[1]. Lu S, et al. Randomized phase Ⅲ trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). ASCO 2021. Abstr9013.
[2]. Cheng Y, et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Target Oncol. 2021;16(2):165-176.
[3]. Wu YL,et al.Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from China. Asia Pac J Clin Oncol. 2012;8(3):232-243.
[4]. Zhou C,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
[5]. Shi YK,et al.First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma(CONVINCE): a phase 3, open-label, randomized study. Ann Oncol.2017;28(10):2443-2450.
[6]. Wu YL,et al.Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations:subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther.2018;11:8575-8587.
[7]. Cheng Y,et al.Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized,open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 2021;154:176-185.
[8]. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTY3MzU5Jml0ZW1JZD1mZjgwODA4MTdjODMxMmM0MDE3YzliYmZjOGRlMDM2MA==
[9]. Soria JC, et al. N Engl J Med. 2018 Jan 11;378(2):113-125.
[10]. Lu S,et al. A multicenter,open-label,single-arm, phase Ⅱ study:The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO). AACR 2020. Abstr CT190.
[11]. 2021版《中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南》